Xaracoll Patent Expiration

Xaracoll is a drug owned by Innocoll Pharmaceuticals. It is protected by 2 US drug patents filed from 2020 to 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 09, 2033. Details of Xaracoll's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11746141 Modified collagen
Jan, 2033

(8 years from now)

Active
USRE47826 Drug delivery device for providing local analgesia, local anesthesia or nerve blockage
May, 2029

(4 years from now)

Active


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Xaracoll's patents.

Given below is the list of recent legal activities going on the following patents of Xaracoll.

Activity Date Patent Number
Patent litigations
Patent Issue Date Used in PTA Calculation 05 Sep, 2023 US11746141
Recordation of Patent eGrant 05 Sep, 2023 US11746141
Recordation of Patent Grant Mailed 05 Sep, 2023 US11746141
Patent eGrant Notification 05 Sep, 2023 US11746141
Mail Patent eGrant Notification 05 Sep, 2023 US11746141
Email Notification 05 Sep, 2023 US11746141
Email Notification 18 Aug, 2023 US11746141
Issue Notification Mailed 16 Aug, 2023 US11746141
Dispatch to FDC 20 Jul, 2023 US11746141
Application Is Considered Ready for Issue 20 Jul, 2023 US11746141


FDA has granted several exclusivities to Xaracoll. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Xaracoll, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Xaracoll.

Exclusivity Information

Xaracoll holds 1 exclusivities. All of its exclusivities have expired in 2023. Details of Xaracoll's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 28, 2023

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Xaracoll is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Xaracoll's family patents as well as insights into ongoing legal events on those patents.

Xaracoll's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Xaracoll's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jan 09, 2033 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Xaracoll Generic API suppliers:

Bupivacaine Hydrochloride is the generic name for the brand Xaracoll. 13 different companies have already filed for the generic of Xaracoll, with Hospira having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Xaracoll's generic

Alternative Brands for Xaracoll

Xaracoll which is used for providing post-surgical analgesia through local anesthesia for up to 24 hours following implantation., has several other brand drugs using the same active ingredient (Bupivacaine Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Purdue Pharma Lp
Chirocaine


Apart from brand drugs containing the same ingredient, some generics have also been filed for Bupivacaine Hydrochloride, Xaracoll's active ingredient. Check the complete list of approved generic manufacturers for Xaracoll





About Xaracoll

Xaracoll is a drug owned by Innocoll Pharmaceuticals. It is used for providing post-surgical analgesia through local anesthesia for up to 24 hours following implantation. Xaracoll uses Bupivacaine Hydrochloride as an active ingredient. Xaracoll was launched by Innocoll Pharms in 2020.

Approval Date:

Xaracoll was approved by FDA for market use on 28 August, 2020.

Active Ingredient:

Xaracoll uses Bupivacaine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Bupivacaine Hydrochloride ingredient

Treatment:

Xaracoll is used for providing post-surgical analgesia through local anesthesia for up to 24 hours following implantation.

Dosage:

Xaracoll is available in implant form for implantation use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
100MG IMPLANT Prescription IMPLANTATION